According to Micah Tapman, managing director at Canopy Ventures, some investors are at risk of letting the cannabis hype train get ahead of itself. He recommends shorting everything for now.

Speaking at MJBizCon INT’L in Toronto, Tapman gave a presentation on valuations where he discussed how to properly weigh risk in the cannabis market as opposed to other investment spaces.

“You need to understand your baseline risk,” he told the Investing News Network (INN) after the presentation. “To put cannabis into perspective … the reality is I could probably make 12 to 15 percent doing much less risky investing in other sectors.”

Tapman also addressed the major boom in cannabis investing in recent months, explaining that some public market investors may be letting their dreams get ahead of themselves.

“I would say short everything right now, because the hype is … we’re at the top of the curve. I can’t imagine that the reality is going to match the expectations of people who put money into the public market,” Tapman said when explaining what investors should know about his evaluation strategy. “I don’t see that reality being close to the dream that people are sort of talking about.”

Keys to evaluating cannabis companies according to Tapman

Many speakers at MJBizCon INT’L echoed the sentiment that the cannabis market is a rapidly evolving and changing environment, and that it will likely be wildly different in as little as a year.

Tapman highlighted this point when discussing how he evaluates which cannabis businesses to invest in.

“The team must be very, very agile. Mentally agile, skill level agile … we know the market will be different tomorrow than it is today,” he told INN. “The number-one way for an investment to fail is for the company to fail,” Tapman continued.

Tapman explained that he seeks teams that are capable of making adjustments to their business models and that can also pivot depending on the dynamics of the market.

With more cannabis companies starting to pursue international — including US-based — interests, he expressed some skepticism, saying varying regulations can put a damper on those efforts.

“It’s very, very challenging to see right now, the public companies; I can’t imagine any of them being a dominant US company,” Tapman said. “It’s not just learning how to do business in the US, which is hard enough, it’s also learning how to do business in all 50 states in order to become a dominant player there.”

Executives for the leading cannabis companies on the Toronto Stock Exchange have expressed interest in the US market, once the drug is completely legal in the country. Cannabis remains an illegal substance on a federal scale, despite several states legalizing its use.

Despite some of the challenges Tapman foresees for players in the cannabis space, he expressed confidence in ancillary businesses that find themselves in a position to thrive from marijuana’s recent market positivity.

“The two big ones are agricultural technologies, which has been an underrepresented area of technical development for a long time, and then the other big one honestly is supply chain management, which also has been underrepresented,” he said.

He explained that ancillary businesses leave room for innovation in the cannabis space that might not be seen otherwise, using Apple (NASDAQ:AAPL) as an example of a company with a successful supply chain strategy.

“They figured out how … to make the aluminum bodies, which then allowed them to sell a laptop for double the price of anybody else, which gave them the margins to get more research and development for really neat stuff,” he explained.

“We’re going to see similar types of innovation coming out of cannabis, whether it’s tracking the supply chain, packaging for eco-friendly stuff that we’re seeing now with the hemp-based plastics. Some really, really neat technologies are coming out around supply chain.”

Don’t forget to look for our coverage of MJBizCon INT’L, with show notes from the floor and exclusive interviews on INN. You can also follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Olivia Da Silva, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less